Retinopathy, small fiber neuropathy (SFN), and encephalopathy associated with recoverin antibodies have not been previously reported as side effects of BNT162b2 vaccination in a patient with HLA-B27-associated spondylarthritis. The patient is a 47-year-old male with a 10-year history of HLA-B27-associated spondylarthritis without recurrence, who developed acute and post-acute COVID vaccination syndrome (ACVS/PACVS) after the first dose of the BNT162b2 vaccine. The PACVS manifested as cerebral disease, eye disease, and SFN. Two years after the onset of the adverse effects, recurrent elevated recoverin antibodies were detected. Despite the administration of various treatments, most symptoms persisted for more than three years, and only a few interventions such as glucocorticoids, hyperbaric oxygen therapy, botulinum toxin, inuspheresis, and HELP (heparin-induced extracorporeal LDL precipitation) apheresis showed a transient beneficial effect. In conclusion, this case offers an example of a collection of symptoms following SARS-CoV-2 vaccination (SC2V) in a patient with a specific autoimmune disorder and positivity for anti-recoverin antibodies. These clinical manifestations may be triggered by an exaggerated immune response known as multisystemic inflammatory syndrome in adults to SC2V. Clinicians should report other similar cases to determine if a pattern exists.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398851PMC
http://dx.doi.org/10.7759/cureus.66881DOI Listing

Publication Analysis

Top Keywords

post-acute covid
8
covid vaccination
8
vaccination syndrome
8
recoverin antibodies
8
hla-b27-associated spondylarthritis
8
anti-recoverin antibody-associated
4
antibody-associated post-acute
4
vaccination
4
syndrome bnt162b2
4
bnt162b2 hla-b27-positive
4

Similar Publications

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system, neurological symptoms were reported both during acute and post-acute COVID-19. Notably, patients with no history of epilepsy or other neurological conditions developed new-onset refractory status epilepticus (NORSE) weeks, months, or even up to a year following the viral infection. While NORSE is uncommon, it carries a high mortality rate and can result in permanent epilepsy.

View Article and Find Full Text PDF

Objectives: Post-COVID-19 condition (PCC), also referred to as Long COVID, has become an emerging public health issue requiring adequate prevention, treatment and management strategies. Evaluating these strategies from the patients' perspective using patient-reported outcome measures (PROMs) is critical. In this systematic review, we aimed to critically appraise and summarise the quality of existing PROMs for PCC, and to identify PROMs that can be recommended for use in future research.

View Article and Find Full Text PDF

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may occur after infection. How often people develop ME/CFS after SARS-CoV-2 infection is unknown.

Objective: To determine the incidence and prevalence of post-COVID-19 ME/CFS among adults enrolled in the Researching COVID to Enhance Recovery (RECOVER-Adult) study.

View Article and Find Full Text PDF

Some of the millions of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have developed new sequelae after recovering from the initial disease, termed post-acute sequelae of coronavirus disease 2019 (PASC). One symptom is anxiety, which is likely due to three etiologies: brain structural changes, neuroendocrine disruption, and neurotransmitter alterations. This review provides an overview of the current literature on the pathophysiological pathways linking coronavirus disease 2019 to anxiety, as well as the possible mechanisms of action in which an increasingly scrutinized treatment method, enhanced external counter-pulsation (EECP), is able to alleviate anxiety.

View Article and Find Full Text PDF

Background: Given the chronic immune activation and inflammatory milieu associated with Long COVID and HIV, we assessed the prevalence of Long COVID in adults living with HIV; and investigated whether adults living with HIV were associated with increased chance of developing Long COVID compared to adults living without HIV.

Methods: In this systematic review and meta-analysis, we searched Medline, EMBASE, CINHAL, PubMed and CENTRAL from inception until June 14th, 2024, for observational studies that measured the prevalence of Long COVID in adults living with HIV and the odds of developing Long COVID following a SARS-CoV-2 infection in people living with HIV compared to people living without HIV. Reviews, case reports, randomised control trials and editorials were excluded.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!